Nano-hole induction by nanodiamond and nanoplatinum liquid, DPV576, reverses multidrug resistance in human myeloid leukemia (HL60/AR)
Authors:
Open Access
- 1 July 2013
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 8 (1) , 2567-2573
Abstract
Recently nanoparticles have been extensively studied and have proven to be a promising candidate for cancer treatment and diagnosis. In the current study, we examined the chemo-sensitizing activity of a mixture of nanodiamond (ND) and nanoplatinum (NP) solution known as DPV576, against multidrug-resistant (MDR) human myeloid leukemia (HL60/AR) and MDR-sensitive cells (HL60). Cancer cells were cultured with different concentrations of daunorubicin (DNR) (1 × 10-9–1 × 10-6 M) in the presence of selected concentrations of DPV576 (2.5%–10% v/v). Cancer cell survival was determined by MTT assay, drug accumulation by flow cytometry and confocal laser scanning microscopy (CLSM), and holes and structural changes by atomic force microscopy (AFM). Co-treatment of HL60/AR cells with DNR plus DPV576 resulted in the reduction of the IC50 to 1/4th. This was associated with increased incidences of holes inside the cells as compared with control untreated cells. On the other hand, HL60 cells did not show changes in their drug accumulation post-treatment with DPV576 and DNR. We conclude that DPV576 is an effective chemo-sensitizer as indicated by the reversal of HL60/AR cells to DNR and may represent a potential novel adjuvant for the treatment of chemo-resistant human myeloid leukemia.Keywords
This publication has 53 references indexed in Scilit:
- The properties and applications of nanodiamondsNature Nanotechnology, 2011
- Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancerBiomaterials, 2008
- A Nonapoptotic Cell Death Process, Entosis, that Occurs by Cell-in-Cell InvasionCell, 2007
- Are Diamond Nanoparticles Cytotoxic?The Journal of Physical Chemistry B, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Phagocytosis of candida albicans by lymphatic tumour cells in vitroActa Histochemica, 2003
- Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cellsCancer Chemotherapy and Pharmacology, 1997
- Paclitaxel (Taxol) and Docetaxel (Taxotere): active chemotherapeutic agents in lung cancerLung Cancer, 1995
- Antineoplastic Drug Resistance in Brain TumorsNeurologic Clinics, 1991
- Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities.The Journal of Immunology, 1982